|1.||Chen, Christopher: 3 articles (02/2012 - 05/2007)|
|2.||Richel, Dick J: 3 articles (05/2011 - 04/2005)|
|3.||Verso, Melina: 3 articles (01/2011 - 10/2009)|
|4.||Agnelli, Giancarlo: 3 articles (01/2011 - 10/2009)|
|5.||Büller, Harry R: 3 articles (04/2010 - 04/2005)|
|6.||Iatsenko, S M: 3 articles (09/2007 - 03/2001)|
|7.||Goddijn, Mariëtte: 2 articles (01/2014 - 04/2010)|
|8.||Di Nisio, Marcello: 2 articles (01/2014 - 05/2011)|
|9.||Middeldorp, Saskia: 2 articles (01/2014 - 04/2010)|
|10.||Mismetti, P: 2 articles (10/2013 - 08/2006)|
09/01/2004 - "Subcutaneous UFH with dose adjusted by activated partial thromboplastin time by means of a weight-based algorithm is as effective and safe as fixed-dose nadroparin for the initial treatment of patients with VTE, including those with pulmonary embolism and recurrent VTE."
05/24/2004 - "Subcutaneous UFH with dose adjusted by activated partial thromboplastin time by means of a weight-based algorithm is as effective and safe as fixed-dose nadroparin for the initial treatment of patients with VTE, including those with pulmonary embolism and recurrent VTE."
07/01/2005 - "Pulmonary embolism was discovered at autopsy in 10 of 63 patients in the nadroparin group and in 17 of 60 in the placebo group [relative risk reduction 0.38, CI (-0.27, +0.70), P=0.13]. "
10/01/1989 - "At the post-mortem examination, carried out in 23 patients (88.5%), two deaths were found to be directly due to pulmonary embolism (0.09%) in the CY 216 group and four (0.18%) in the placebo group. "
04/01/1997 - "In clinical trials conducted in older patients (mean age usually > 60 years), nadroparin was at least as effective as UFH in preventing deep vein thrombosis (DVT) and pulmonary embolism after major general or orthopaedic surgery, and in bedridden medical patients. "
|2.||Venous Thrombosis (Deep-Vein Thrombosis)
01/01/2003 - "Deep vein thrombosis can be effectively treated or prevented with nadroparin without any serious adverse events. "
03/01/1994 - "Antithrombotic treatment of superficial venous thromboses with calcium nadroparin is well tolerated and appears to be associated with a greater improvement in symptoms and signs, in the short and mid-terms, than that obtained with an oral non-steroidal anti-inflammatory."
08/01/2010 - "Detection and Prevention of Post-Operative Deep Vein Thrombosis [DVT] Using Nadroparin Among Patients Undergoing Major Abdominal Operations in India; a Randomised Controlled Trial."
11/01/1992 - "The study deals with the efficiency and the cost of an ambulatory treatment of deep venous thrombosis by means of Fraxiparine, contention and phlebotonics. "
01/01/2010 - "After 2-6 weeks of antepartal deep vein thrombosis (DVT) treatment the dose of nadroparin was reduced to intermediate level. "
|3.||Body Weight (Weight, Body)
04/01/1993 - "As a good relationship was found between plasma anti-Xa activity and body weight, adoption of a personalized dosage schedule might improve efficacy of CY 216 prophylaxis."
01/01/2015 - "Twenty-eight morbidly obese and seven non-obese patients receiving 5700 IU and 2850 IU subcutaneous (s.c.) nadroparin for surgery, respectively, were included with a mean total body weight (TBW) of 135 kg (range 72-252 kg). "
01/01/2015 - "In order to guide dosing in this patient group, a pharmacodynamics model is developed for nadroparin in morbidly obese and non-obese patients using anti-Xa levels as an endpoint, thereby characterizing the influence of excessive body weight on different pharmacodynamic model parameters. "
06/01/2005 - "administration of either fixed prophylactic doses (2850 a-Xa IU) or body-weight adjusted therapeutic doses of nadroparin once daily for 1 month. "
05/01/2003 - "Thromboprophylactic regimen was based on a prolonged subcutaneous administration of nadroparin (for 40 days after surgery) and was used in all patients, with a dose based on body weight. "
01/01/2003 - "Tolerability of percutaneous coronary interventions in patients receiving nadroparin calcium for unstable angina or non-Q-wave myocardial infarction: the Angiofrax study."
04/01/1997 - "Subcutaneous nadroparin, at dosages similar to those used for the treatment of DVT, produced promising results in older patients with pulmonary embolism, acute ischaemic stroke or unstable angina. "
01/01/2003 - "These results suggest that CA and PCIs can be performed safely in patients being treated for unstable angina or non-Q-wave myocardial infarction receiving nadroparin pre- and post-coronary procedure and/or intervention, substituted by unfractionated heparin for the duration of the intervention."
11/01/1999 - "Treatment with nadroparin for 6+/-2 days provides similar efficacy and safety to treatment with unfractionated heparin, for the same period, in the therapeutic management of acute unstable angina or non-Q wave myocardial infarction, and may be easier to administer. "
11/01/2003 - "Enoxaparin and nadroparin, accompanied by GP IIb/IIIa inhibitor therapy, have similar effects on the development of major cardiac events in patients presenting with unstable angina and high-risk characteristics."
03/01/2003 - "High efficacy of fraxiparine application in prophylactical dosage for prevention of the venous thromboembolism occurrence was noted."
12/01/2001 - "Our results indicate that 0.6 ml (5700 IU) of nadroparin once daily is safe and well-tolerated, and it is as effective in prophylaxis of venous thromboembolism as the higher dose of 1 ml (9500 IU), in such high risk patients."
05/01/1998 - "None of the patients had clinical recurrent venous thromboembolism during the initial treatment with nadroparin. "
03/01/2006 - "Fraxiparin and spinal anesthesia were found to promote the lower incidence of venous thromboembolism. "
06/01/2011 - "Calcium nadroparin is a low molecular weight heparin usually administered in patient with venous thromboembolism at a dose level of 180 IU/kg/daily. "
|1.||Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)
|3.||Dalteparin (Dalteparin Sodium)
|5.||Aspirin (Acetylsalicylic Acid)
|6.||certoparin (certoparin sodium)
|1.||Renal Dialysis (Hemodialysis)
|3.||Renal Replacement Therapy (Therapies, Renal Replacement)
|4.||Drug Therapy (Chemotherapy)